SARS-CoV-2 evolves to reduce but not abolish neutralizing action

Zhang, Yandi1; Ndzouboukou, Jo-Lewis B.1; Lin, Xiaosong1; Hou, Hongyan2; Wang, Feng2; Yuan, Leyong3; Gan, Mengze1; Yao, Zongjie1; Fu, Hui1; Cao, Jinge1; Fan, Xionglin1

2022-10-01

10.1002/jmv.28207

JOURNAL OF MEDICAL VIROLOGY   Impact Factor & Quartile

0146-6615

1096-9071

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) have prolonged coronavirus disease 2019 (COVID-19) pandemic by escaping pre-existing immunity acquired by natural infection or vaccination. Elucidation of VOCs' mutation trends and evasion of neutralization is required to update current control measures. Mutations and the prevalence of VOCs were analyzed in the global immunization coverage rate context. Lentivirus-based pseudovirus neutralization analysis platforms for SARS-CoV-2 prototype strain (PS) and VOCs, containing Alpha, Beta, Gamma, Delta, and Omicron, were constructed based on the spike protein of each variant and HEK 293T cell line expressing the human angiotensin-converting enzyme 2 (hACE2) receptor on the surface, and an enhanced green fluorescent protein reporter. Serum samples from 65 convalescent individuals and 20 WIBP-CorV vaccine recipients and four therapeutic monoclonal antibodies (mAbs) namely imdevimab, casirivimab, bamlanivimab, and etesevimab were used to evaluate the neutralization potency against the variants. Pseudovirus-based neutralization assay platforms for PS and VOCs were established, and multiplicity of infection (MOI) was the key factor influencing the assay result. Compared to PS, VOCs may enhance the infectivity of hACE2-293T cells. Except for Alpha, other VOCs escaped neutralization to varying degrees. Attributed to favorable and emerging mutations, the current pandemic Omicron variant of all VOCs demonstrated the most significant neutralization-escaping ability to the sera and mAbs. Compared with the PS pseudovirus, Omicron had 15.7- and 3.71-fold decreases in the NT50 value (the highest serum dilution corresponding to a neutralization rate of 50%); and correspondingly, 90% and 43% of immunization or convalescent serum samples lost their neutralizing activity against the Omicron variant, respectively. Therefore, SARS-CoV-2 has evolved persistently with a strong ability to escape neutralization and prevailing against the established immune barrier. Our findings provide important clues to controlling the COVID-19 pandemic caused by new variants.

COVID-19 immune escape neutralizing antibodies SARS-CoV-2 VOCs

SCI

English

Others

Virology

Virology

WOS:000869811200001

WILEY

MICROBIOLOGY

Web of Science

1.Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan 430030, Peoples R China
2.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Lab Med, Wuhan, Peoples R China
3.Southern Univ Sci & Technol Hosp, Dept Clin Lab, Shenzhen, Peoples R China

Zhang, Yandi,Ndzouboukou, Jo-Lewis B.,Lin, Xiaosong,et al. SARS-CoV-2 evolves to reduce but not abolish neutralizing action[J]. JOURNAL OF MEDICAL VIROLOGY,2022.

Zhang, Yandi.,Ndzouboukou, Jo-Lewis B..,Lin, Xiaosong.,Hou, Hongyan.,Wang, Feng.,...&Fan, Xionglin.(2022).SARS-CoV-2 evolves to reduce but not abolish neutralizing action.JOURNAL OF MEDICAL VIROLOGY.

Zhang, Yandi,et al."SARS-CoV-2 evolves to reduce but not abolish neutralizing action".JOURNAL OF MEDICAL VIROLOGY (2022).